The recent expansion of mRNA vaccine and therapeutic candidates under development in response to the COVID-19 pandemic has prompted significant interest in improving analytical methodologies for mRNA analysis.
This webinar showcases a platform’s applications to mRNA analytics, with a focus on its applicability as an identity and mRNA content assay for multivalent mRNA vaccines using the newly released nuIQ product line. The platform enables the confirmation of identity and simultaneous quantification of all constructs in multivalent naked mRNA samples and lipid nanoparticle (LNP)-encapsulated mRNA samples in under two hours.
In addition to highlighting the platform’s various applications in mRNA analytics, a case study demonstrates an assay capable of specific and simultaneous quantification of each of four influenza hemagglutinin (HA) mRNA constructs relevant to seasonal influenza vaccines.
The mRNA fluIQ assay was specifically designed for universal reactivity with HA mRNAs, regardless of source or codon optimization scheme, and provided a robust and efficient tool for streamlined mRNA quantification. In addition, they will highlight recent joint published work with Pfizer on a custom assay for identity and quantity in a multivalent mRNA vaccine candidate.
Attendees will learn about how the VaxArray platform streamlines the identification and measurement of multivalent naked or LNP-encapsulated mRNA in under two hours, enhancing efficiency compared to existing technologies. They will also gain insights from a recent joint publication with Pfizer as well as a case study showcasing the platform’s capability to universally quantify multivalent influenza HA mRNA constructs.
Register for this webinar to explore how this innovative platform can support rapid and reliable mRNA analytics in diverse applications.
Keywords: Drug Development, Clinical Research, Analytical Testing, Laboratory Technology, Bioanalytical Testing, mRNA Vaccines, mRNA Therapeutics, mRNA Vaccine, mRNA Technology